Open access · US-GOV via ClinicalTrials.gov Clinical trial

Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With GLP-1 Receptor Agonist Treatment

Authors not listed

State University of New York at Buffalo · 2022

Dysbiosis Exercise Human Randomized controlled trial

Abstract

This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-29 MST

Cite this

APA

Anonymous. (2022). Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With GLP-1 Receptor Agonist Treatment. <em>State University of New York at Buffalo</em>. https://clinicaltrials.gov/study/NCT05302596

Vancouver

Anonymous. Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With GLP-1 Receptor Agonist Treatment. State University of New York at Buffalo. 2022.

BibTeX

@misc{anon2022Preser, title = {Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With GLP-1 Receptor Agonist Treatment}, author = {Anonymous}, journal = {State University of New York at Buffalo}, year = {2022}, }